Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Spondyloarthritis
How do you manage flares of axial spondyloarthritis in patients already on biologic therapy who were previously controlled?
Does a flare always indicate treatment failure?
Related Questions
How would you approach a patient with axial spondyloarthritis who develops new-onset proteinuria?
How would you approach the management of HLA-B27-associated recurrent uveitis and inflammatory back pain with a recent history of melanoma?
What is your approach to differentiating tender spots (as in fibromyalgia) and enthesitis (as in axSpA)?
Do you utilize serial MRI imaging in patients with axial spondyloarthritis to ensure good disease control or do you rely on symptoms and physical exam to assess treatment response?
How would you treat a patient with psoriatic arthritis who developed disseminated histoplasmosis while on adalimumab and previously failed all non-biologic DMARDs?
In a patient with isolated HLA B27+ anterior uveitis, how long would you continue immunosuppressive therapy?
Do you use biologic DMARDs for active axial spondyloarthritis in transplant patients on long-term anti-rejection therapy?
Would you transition a patient with axial spondyloarthritis to a biologic if their axial symptoms were controlled with an NSAID, but they also required a PPI to control dyspepsia/GERD caused by the NSAID?
Do you consider it safe to continue adalimumab for spondyloarthritis in a patient who develops localized melanoma if the adalimumab has worked well?
How would you manage axial spondyloarthritis in a patient who was doing well on TNF inhibitor therapy then developed a new solid organ malignancy while on treatment?